The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an ...

The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi ...

The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.

An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is ...

Yet one factor remains consistently underestimated: physical connectivity or fluid management. The tubing, connectors, ...

A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one ...

One lawyer involved noted how it's yet another example of Paragon and key investor Fairmount — which have helped transform ...

Prosecutors say the company filled unnecessary prescriptions that fueled the opioid epidemic. A spokesperson for CVS said the company admitted to no wrongdoing and “strongly disagreed” with the case’s ...

In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein ...

A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is ...

Part of a wave of young biotechs employing AI to accelerate research, the company claimed in regulatory filings that its approach has the potential to “disrupt legacy drug discovery paradigms.” ...

Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies the company — now known as Lakefront Biotherapeutics — divested in a strategic overhaul.